Abstract Since 2012, non-invasive prenatal testing (NIPT) using cell-free DNA from maternal plasma is applied all over the world as highly efficient first-line or contingent screening approach for trisomy 13, 18 and 21. With further technical development has expanded to other genetic conditions such sex chromosome anomalies (SCAs), rare autosomal trisomies (RATs), microdeletions/microduplicatio...